Chronic renal failure patient with hypertension under going rennin-angiotensin treatment (ARB/ACE-inhibitor) (preservation period)
Conditions
Interventions
Another antihypertensive agents (aliskiren is excluded) are oral-administrating or ARB/ACE inhibitor is increased in patients under the treatment of ARB/ACE inhibitor. If BP dose not reach to lower
Sponsors
Kure Kyousai Hospital
Chuo Naika Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Fulfill all the following requirements at the time of the examination beginning. (1) Chronic renal failure patient with hypertension (preservation period), eGFR <60ml/min/1.73m2,and urinary protein is positive. (2) Patients under the treatment with ARB or ACE inhibitor (administrating for 6 months at the time of the examination beginnig at least.) (3)Patients who can acquire agreement with document when participating in research
Exclusion criteria
Exclusion criteria: Patient who much as one of the following items excludes from the examination object. (1)Active artery disease(within 6months of the clinical research beginning, patients who have unstable AP,MI,TIA,cerebrovascular disease,coronary bypass) (2)Patients administrating with Cyclosporin (3) Woman who has pregnant or possibility of pregnancy. (4) Patients who is important or unstable physically or mentally, and who is considerd to ruin a safety of patient and a participation to clinical research by the research doctor. (5)Additionally, patients who thought that doctor is improper.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1)Comparison with urinary protein and serum Cr between aliskiren group and non-aliskiren group. (2)Comparison with urinary protein and serum Cr before and after administering aliskiren in aliskiren group. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Office blood pressure(BP) (2)Estimated glomerular filtration rate(eGFR)calculated using the modified MDRD formula in the Japanese Society of Nephrology:eGFR(ml/min/1.73m2)=194 x age -0.287 x serum Cr -1.094(multiply by 0.739 in female) (3)CCr (4)Dialysis shift rate (5)Cardiovascular events (Stroke or transient ischaemic attack,New or recurrent acute myocardial infection,New occurrence or exacerbation of angina pectoris needing hospitalization,New occurrence or exacerbation of heart failure needing hospitalization,All-cause mortality) | — |
Countries
Japan
Contacts
Public ContactTakao Masaki
Kure Kyousai Hospital Hiroshima University Hospital
Outcome results
None listed